Sunitinib in the treatment of thyroid cancer

SM Ferrari, M Centanni, C Virili… - Current medicinal …, 2019 - ingentaconnect.com
Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with
low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and …
被引用次数：87 相关文章

Sunitinib in the treatment of thyroid cancer

SM Ferrari, M Centanni, C Virili, M Miccoli… - CURRENT MEDICINAL …, 2019 - arpi.unipi.it
BACKGROUND: Sunitinib (SU11248) is an oral, small-molecule, multi-targeted tyrosine
kinase inhibitor (TKI), that inhibits receptors for platelet-derived growth factor (PDGF-Rs) and …

Sunitinib in the Treatment of Thyroid Cancer

SM Ferrari, M Centanni, C Virili… - Current medicinal …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with
low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and …

Sunitinib in the Treatment of Thyroid Cancer.

SM Ferrari, M Centanni, C Virili, M Miccoli… - Current Medicinal …, 2019 - europepmc.org
Background Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with
low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and …

Sunitinib in the treatment of thyroid cancer

SM Ferrari, M Centanni, C Virili, M Miccoli… - CURRENT …, 2019 - iris.uniroma1.it
Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with
low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and …
[PDF] unipi.it

[PDF][PDF] Sunitinib in the treatment of thyroid cancer

FS Martinaa, C Marcob, V Camillab, M Marioa… - arpi.unipi.it
Abstract Background: Sunitinib (SU11248) is an oral, small-molecule, multi-targeted tyrosine
kinase inhibitor (TKI), that inhibits receptors for platelet-derived growth factor (PDGF-Rs) and …